VTA-110 / Vita Therap - LARVOL DELTA

Israeli COVID cure? Researchers hope peptide treatment could slow disease (The Jerusalem Post) - "A group of Israeli researchers have launched a Phase II study of a drug that they believe could keep patients off mechanical ventilation and speed their recovery....The trial is using TXA127, a pharmaceutical formulation of angiotensin 1-7 developed by the US company Constant Therapeutics LLC....The Phase II trial was approved by the Health Ministry and will involve 120 hospitalized COVID-19 patients whose condition is defined as moderate. Sixty patients will receive the treatment and 60 a placebo."

Trial status • Infectious Disease • Novel Coronavirus Disease

Vita Therapeutics receives Orphan Drug Designation from FDA for new novel treatment (PRNewswire) - "Vita Therapeutics...announced today that it received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for VTA-110, a novel regenerative therapy for the treatment of Duchenne's Muscular Dystrophy (DMD)...The company plans to continue to progress this treatment towards clinical trials and plans to bring it forward for other congenital muscular dystrophy diseases as well..."

New trial • Orphan drug • Duchenne Muscular Dystrophy